Quality of life of hepatitis B virus surface antigen-positive patients with suppressed viral replication: comparison between inactive carriers and nucleot(s)ide analog-treated patients

Eur J Gastroenterol Hepatol. 2018 Jan;30(1):14-20. doi: 10.1097/MEG.0000000000000999.

Abstract

Objective: Hepatitis B virus infection is a relevant health problem with more than 400 million infected people worldwide. Our aim was to analyze quality of life of hepatitis B virus surface antigen-positive patients in inactive status or treated with antivirals.

Patients and methods: Patients referred to our center between February and October 2016 were prospectively enrolled. Half-structured interview was used for examining psychological symptoms and Illness Behavior Questionnaire for exploring attitudes toward illness. We used World Health Organization Quality of Life-short version survey for studying quality of life and logistic regression to find possible predictors of nonadequate quality of life.

Results: The study involved 102 patients. At Illness Behavior Questionnaire test, psychological perception of illness (21.6%), and denial of illness itself (13.7%) were the most frequent conditions. Inactive and treated subgroups were comparable for almost all variables and scores, but patients on treatment were significantly more often male, older, and cirrhotic. Sleep disturbance emerged as an independent predictor of inadequate quality of life in Physical health, anxiety in Social relationship, and both anxiety and hostility in Environmental health domain.

Conclusion: Inactive carriers and patients on treatment showed the same global quality of life, but the second group was older and more frequently with an advanced liver disease. Further studies might specifically evaluate the impact of antiviral therapy on quality of life.

Publication types

  • Comparative Study

MeSH terms

  • Adult
  • Age Factors
  • Aged
  • Antiviral Agents / adverse effects
  • Antiviral Agents / therapeutic use*
  • Biomarkers / blood
  • Chi-Square Distribution
  • Cross-Sectional Studies
  • Female
  • Hepatitis B / blood*
  • Hepatitis B / drug therapy*
  • Hepatitis B / psychology
  • Hepatitis B / virology
  • Hepatitis B Surface Antigens / blood*
  • Hepatitis B virus / drug effects*
  • Hepatitis B virus / growth & development
  • Hepatitis B virus / immunology
  • Humans
  • Italy
  • Logistic Models
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Nucleosides / adverse effects
  • Nucleosides / therapeutic use*
  • Nucleotides / adverse effects
  • Nucleotides / therapeutic use*
  • Prospective Studies
  • Quality of Life*
  • Risk Factors
  • Surveys and Questionnaires
  • Sustained Virologic Response*
  • Time Factors
  • Treatment Outcome
  • Virus Replication / drug effects*

Substances

  • Antiviral Agents
  • Biomarkers
  • Hepatitis B Surface Antigens
  • Nucleosides
  • Nucleotides